Dr. Halka is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2401 S 31st St
Temple, TX 76508Phone+1 254-724-2111Fax+1 254-724-1530
Education & Training
- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 1983 - 1986
- Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Internal Medicine, 1980 - 1983
- Creighton University School of MedicineClass of 1980
Certifications & Licensure
- TX State Medical License 1993 - 2025
- NJ State Medical License 1981 - 2003
- PA State Medical License 1983 - 1990
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2016 Dec 28
Publications & Presentations
PubMed
- 47 citationsEculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndromeMaro Ohanian, Christian Cable, Kathleen Halka
Clinical Pharmacology. 2011-05-24 - 867 citationsLong-term safety and efficacy of factor IX gene therapy in hemophilia BAmit C. Nathwani, Ulreke M Reiss, Edward G. D. Tuddenham, Cecilia Rosales, Pratima Chowdary
The New England Journal of Medicine. 2014-11-20 - 22 citationsReduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case reportMaro Ohanian, Christian Cable, Kathleen Halka
Clinical Pharmacology. 2011-11-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: